Antimicrobial Peptide-Selenium Nanoparticles for Resistant Bacteria
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antimicrobial agents, particularly antibiotics, face challenges such as antibiotic resistance and toxicity issues, necessitating the development of new broad-spectrum antimicrobial agents effective against both Gram-positive and Gram-negative bacteria, including resistant strains, with reduced susceptibility to resistance development.
Innovation Solution
A selenium nanoparticle (SeNP) core combined with one or more superficially located antimicrobial peptides (AMPs), such as ε-poly-L-lysine, forming SeNP-ε-PL, which exhibits enhanced antibacterial activity through electrostatic interactions, membrane disruption, and reactive oxygen species production, while minimizing toxicity to human cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used to eradicate bacteria, then bacterial infections are cured, but antibiotic resistance develops rapidly
Solution Approach 1:
The patent combines selenium nanoparticles with antimicrobial peptides to create a composite antimicrobial agent. The selenium nanoparticle core provides oxidative stress and membrane disruption, while the AMP shell contributes to membrane disruption and pore formation. This composite structure attacks bacteria through multiple mechanisms simultaneously, making it difficult for bacteria to develop resistance through single-mutation pathways.
2Reliability
If silver nanoparticles are used as antimicrobial agents, then broad-spectrum antibacterial activity is achieved, but toxicity to mammalian cells increases
Solution Approach 1:
The patent changes the material composition from silver nanoparticles to selenium nanoparticles. Selenium is an essential trace element for mammals, and the patent demonstrates that SeNPs at appropriate concentrations promote human dermal fibroblast proliferation rather than causing toxicity. This parameter change in material composition maintains antimicrobial effectiveness while reducing mammalian cell toxicity.
3Reliability
If Gram-negative bacteria are targeted with traditional antimicrobials, then treatment is difficult due to outer membrane barrier, but new agents need to penetrate this barrier effectively
Solution Approach 1:
The patent segments the antimicrobial mechanism into two functional parts: the selenium nanoparticle core that generates oxidative stress and disrupts membranes, and the AMP shell that facilitates membrane interaction and pore formation. This segmentation allows the agent to overcome the Gram-negative outer membrane barrier through the AMP's cell-penetrating capabilities while the core provides the antimicrobial killing mechanism.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
SeNP-ε-PL demonstrates broad-spectrum antibacterial activity against both Gram-positive and Gram-negative bacteria, including resistant strains, with reduced likelihood of resistance development and lower cytotoxicity, making it a promising new generation antimicrobial agent.
Implementation Method 1
reactive oxygen species production
Implementation Method 2
electrostatic interactions
Data Source
AI summary
An antimicrobial agent comprising a selenium nanoparticle (SeNP) core and one or more superficially located antimicrobial peptide/s (AMP). The or each AMP may comprise an excess of positively charged amino acids compared to negatively charged amino acids and the AMP may comprise peptides from classes selected from polylysine, such as ε-poly-L-lysine (ε-PL), polyarginine, aurein, ovispirin, melittin, magainin, cecropin, andropin, moricin, ceratotoxin, melittin, magainin, dermaseptin, bombinin, brevinin, esculentins, buforin, cathelicidin, abaecin, apidaecin, prophenin and indolicidin. Products comprising such agents, methods of producing the agents and methods of killing or retarding growth of microorganisms exposed to the agents are also disclosed.